Insybio
Austin, US · Founded 2017 · Delaware corporation
InSyBio develops the InSyBio Suite, a software platform that applies machine learning and computational intelligence to biological and biomedical data analysis, including bioinformatics and drug development applications. The company builds tools for analyzing protein, biomarker, and other biological datasets, and collaborates on EU research projects.
Founders & leadership
Insybio was founded in 2017 by Christos, Konstantinos, and Aigli.
Reported raises · per SEC filings
Form D private placements$550K disclosed across 1 round · 2018
▶$550KraisedAug 2018 · 5 investors · Other TechnologyRule 506(b)
▶$550KraisedAug 2018 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Angelos AngelouExecutive Officer
- Labros DigonisExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $550K
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
VeriSIM Life3 shared keywordsVeriSIM uses machine learning and computational simulation to accelerate drug development, replacing traditional trial-and-error experimentation with computational prediction to improve success rates and reduce animal testing. The company serves pharmaceutical partners and research institutions developing new medicines.
Elucidata3 shared keywordsElucidata is a company oriented around supporting scientific research, emphasizing making users' research more efficient and respecting the scientific method. The available page content does not describe its concrete products or offerings in detail.
PrecisionLife3 shared keywordsPrecisionLife uses genetic analysis and AI to decode the underlying disease mechanisms of complex chronic diseases beyond oncology, offering diagnostic and prognostic tools (Mechanostics) to stratify patients. It serves healthcare and drug developers by identifying novel therapeutic targets, predicting treatment response, and enriching clinical trials.
Genomind3 shared keywordsGenomind provides pharmacogenetic testing and precision medicine software to help healthcare providers tailor medication prescriptions based on patients' genetic profiles, lifestyle, and environment. The platform integrates genetic data with clinical expertise to reduce adverse drug events and improve treatment outcomes across individual and population health settings.
Sonrai Analytics3 shared keywordsSonrai Analytics provides expert-led analysis of molecular, imaging, and clinical data within a secure, governed Trusted Research Environment to generate decision-ready evidence for precision medicine programs. It serves translational, clinical, and data teams across drug development—covering target identification, patient stratification, and translational biomarker analysis.
Companies competing with Insybio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Insybio do?
- InSyBio develops the InSyBio Suite, a software platform that applies machine learning and computational intelligence to biological and biomedical data analysis, including bioinformatics and drug development applications. The company builds tools for analyzing protein, biomarker, and other biological datasets, and collaborates on EU research projects.
- Who founded Insybio?
- Insybio was founded by Christos, Konstantinos, Aigli in 2017.
- How much funding has Insybio raised?
- Insybio has disclosed $550K raised across 1 round.
- Where is Insybio headquartered?
- Insybio is headquartered in Austin, US.